Establishing the role of cytokine therapy in advanced renal cell carcinoma

BJU International

Volumn 101, Issue 9, 2008, Pages 1063-1070

  Gore, Martin E ^a,c   De Mulder, Pieter ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Interferon ; Interleukin 2; Renal cell carcinoma; Therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CYTOKINE; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER;

ACUTE TOXICITY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG TOXICITY; MONOTHERAPY; MYALGIA; NAUSEA; OLIGURIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RASH; SHORT SURVEY; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; TREATMENT OUTCOME;

EID: 41849123889     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07435.x     Document Type: Short Survey

References (54)

1. De Mulder PH, van Herpen CM, Mulders PA. Current treatment of renal cell carcinoma. Ann Oncol 2004 15 : 319 28
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 16 : 481 8
3. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J Clin 2006 56 : 106 30
4. Reis LAG, Harkins D, Krapcho M et al. Seer Cancer Statistics Review, 1975-2003. National Cancer Institute, 2007. Available at: http://seer.cancer. gov/csr/1975-2002/ Based on November 2005 SEER data submission, posted to the SEER website. Accessed 15 February 2007
5. Gleave ME, Elhilali M, Fradet Y et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998 338 : 1265 71
6. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992 148 : 1247 8
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000 163 : 408 17
8. Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985 45 : 863 71
9. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995 45 : 758 62
10. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999 17 : 2859 67
11. Steineck G, Strander H, Carbin BE et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990 29 : 155 62
12. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005 1 : CD001425
13. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999 353 : 14 7
14. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002 20 : 289 96
15. Fossa SD, Martinelli G, Otto U et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992 3 : 301 5
16. Kinouchi T, Sakamoto J, Tsukamoto T et al. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol 2006 132 : 499 504
17. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998 338 : 1272 8
18. Sagaster P, Micksche M, Flamm J, Ludwig H. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995 6 : 999 1003
19. Aass N, De Mulder PH, Mickisch GH et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005 23 : 4172 8
20. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001 85 : 1130 6
21. Infergen: Summary of product characteristics. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/infergen/infergen.htm. Accessed 16 November 2006
22. Proleukin. Summary of product characteristics. Available at: http://www.proleukin-international.com/development/pdf/SmPc.pdf. Accessed 17 November 2006
23. National Comprehensive Guidelines Network. Kidney cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. Accessed 15 June 2007
24. Halbert RJ, Figlin RA, Atkins MB et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 2006 107 : 2375 83
25. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985 313 : 1485 92
26. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004 10 : 6342S 6S
27. Spanknebel K, Cheung KY, Stoutenburg J et al. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2. Ann Surg Oncol 2005 12 : 381 90
28. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000 6 : S55 7
29. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995 13 : 688 96
30. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005 23 : 133 41
31. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003 21 : 3127 32
32. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998 228 : 307 19
33. Dutcher JP. Is high-dose interleukin-2 the treatment of choice for metastatic renal carcinoma? Kidney Cancer J 2003 1 : 5 12
34. Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program. Ann Oncol 2006 17 : 25IN Abstract
35. Figlin R, Gitlitz B, Franklin J et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997 3 : S92 7
36. Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2003 46 : S33 9
37. Negrier S, Gomez F, Douillard JY et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol 2005 23 : 161 5
38. Padrik P. Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 2003 20 : 325 34
39. Upton MP, Parker RA, Youmans A et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005 28 : 488 95
40. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002 20 : 2376 81
41. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003 9 : 802 11
42. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005 11 : 3714 21
43. Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer 2005 4 : 181 6
44. Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006 24 : 1169 77
45. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 1997 2005
46. Anonymous. Roferon-α (IFN-α-2α, recombinant). Prescribing information. Available at: http://www.rxmed.com/b.main/b2. pharmaceutical/b2.1.monographs/CPS-Monographs/CPS-(GeneralMonographs-R)/roferon. html. Accessed 15 February 2007
47. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
48. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
49. Hudes G, Carducci M, Tomczac P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006 24 : Lba4 (Abstract)
50. Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007 25 : 3 (Abstract)
51. Dhanda R, Gondek K, Song J et al. A quality of life, symptoms and survival comparison in kidney cancer patients receiving sorafenib versus placebo. Ann Oncol 2006 17 : 447PD (Abstract)
52. Szczylik C, Demkow T, Staehler M et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007 25 : 5025 (Abstract)
53. Ryan CW, Bukowski RM, Figlin RA et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients (pts). J Clin Oncol 2007 25 : 5096 (Abstract)
54. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 2007 25 : 5104 (Abstract)